增生性瘢痕形态学观察及血管内皮生长因子和转化生长因子β激活性激酶1表达的检测与意义

doi:10.3881/j.issn.1000-503X.2015.04.014

Acta Academiae Medicinae Sinica

Acta Academiae Medicinae Sinica ›› 2015, Vol. 37 ›› Issue (4): 446-450.doi: 10.3881/j.issn.1000-503X.2015.04.014

• Orginal Article • Previous Articles Next Articles

Morphology of Hypertrophic Scar Tissues and Expressions of Vascular Endothelial Growth Factor and Transforming Growth Factor Beta Activated Kinase 1 in These Tissues

Yu-fei ZHANG¹, Hou-zhong LI², Xue-yong WANG³, Hong-chuang MA¹, Yan WU¹, Xiao-huan YUAN¹, Yan-hui CHU¹()

¹Medical Research Center,Mudanjiang Medical University,Mudanjiang,Heilongjiang 157011,China
²Department of Pharmacology,Mudanjiang Medical University,Mudanjiang,Heilongjiang 157011,China
³Department of Burn Surgery,the 209 Hospital of Chinese People’s Liberation Army,Mudanjiang,Heilongjiang 157011,China

Received:2015-01-19 Online:2015-05-25 Published:2015-08-31

Abstract

Abstract: Objective

To observe the morphology of hypertrophic scar tissue and explore the expressions and distribution of vascular endothelial growth factor(VEGF)and transforming growth factor beta activated kinase 1(TAK1)in these tissues.

Method

Hematoxylin-eosin staining,Masson staining,immunofluorescence,and real-time polymerase chain reaction were used to detect the localization and expression of VEGF and TAK1 in 15 hypertrophic scar tissues and 10 normal skin tissues.

Results

Morphological observation showed that the dermal fibroblasts in hypertrophic scar were disorderly and densely arranged(compared to the normal skin). Immunofluorescence displayed that the expressions of VEGF and TAK1 in hypertrophic scar tissue were higher than in normal skin tissues. Real-time polymerase chain reaction showed the mRNA expressions of both VEGF and TAK1 were significantly higher in hypertrophic scar tissue than in normal tissue(P<0.01,P<0.05,respectively).

Conclusions

Hypertrophic scar tissue has higher collagen fibrosis degree and higher TAK1 and VEGF expressions than the normal skin. VEGF and TAK1 can be used as the reference indicators for the diagnosis and differential diagnosis of hypertrophic scar and serve as new therapeutic targets.

Key words: hypertrophic scar, collagen fibrosis, vascular endothelial growth factor, transforming growth factor-beta-activated kinase 1

CLC Number:

R619.6

Yu-fei ZHANG, Hou-zhong LI, Xue-yong WANG, Hong-chuang MA, Yan WU, Xiao-huan YUAN, Yan-hui CHU. Morphology of Hypertrophic Scar Tissues and Expressions of Vascular Endothelial Growth Factor and Transforming Growth Factor Beta Activated Kinase 1 in These Tissues[J].Acta Academiae Medicinae Sinica, 2015, 37(4): 446-450.

Figures/Tables 5

Fig 1

Fig 2

Fig 3

Fig 4

Fig 5

References 17

[1]	Wilgus TA,Ferreira AM,Oberyszyn TM,et al.Regulation of scar formation by vascular endothelial growth factor[J]. Lab Invest,2008,88(6):579-590.
[2]	Delaney JR,Mlodzik M.TGF-beta activated kinase-1:new insights into the diverse roles of TAK1 in development and immunity[J]. Cell Cycle,2006,5(24):2852-2855.
[3]	Sakurai H.Targeting of TAK1 in inflammatory disorders and cancer[J]. Trends Pharmacol Sci,2012,33(10):522-530.
[4]	Pitzer GB,Patel KG.Proper care of early wounds to optimize healing and prevent complication[J]. Facial Plast Surg Clin North Am,2011,19(3):491-504.
[5]	Wolfram D,Tzankov A,Pülzl P,et al.Hypertrophic scars and keloids-a review of their pathophysiology,risk factors,and therapeutic management[J]. Dermatol Surg,2009,35(2):171-181.
[6]	Matthew RJ,Gautam GS,Joseph PA,et al.Novel therapies for scar reduction and regenerative healing of skin wounds[J]. Trends Biotechnol,2008,4(26):173-180.
[7]	Johnson KE,Wilgus TA.Vascular endothelial growth factor and angiogenesis in the regulation of cutaneous wound repair[J]. Adv Wound Care(New Rochelle),2014,3(10):647-661.
[8]	Qing C,Wang ZY,Song F,et al.Dynamic biological changes in fibroblasts during hypertrophic scar formation and regression[J]. Int Wound J,2014 [Epub ahead of print].
[9]	Keswani SG,Balaji S,Le LD,et al.Role of salivary vascular endothelial growth factor(VEGF)in palatal mucosal wound healing[J]. Wound Repair Regen,2013,21(4):554-562.
[10]	Wietecha MS,DiPietro LA.Therapeutic approaches to the regulation of wound angiogenesis[J]. Adv Wound Care(New Rochelle),2013,2(3):81-86.
[11]	Schuman J,Chen Y,Podd A,et al.A critical role of TAK1 in B-cell receptor-mediated nuclear factor kappa B activation[J]. Blood,2009,113(19):4566-4574.
[12]	Kajino Sakamoto R,Inagaki M,Lippert E,et al.Enterocyte-derived TAK1 signaling prevents epithelium apoptosis and the development of ileitis and colitis[J]. J Immunol,2008,181(2):1143-1152.
[13]	Omori E,Matsumoto K,Sanjo H,et al.TAK1 is a master regulator of epidermal homeostasis involving skin inflammation and apoptosis[J]. J Biol Chem,2006,281(28):19610-19617.
[14]	Inokuchi S,Aoyama T,Miura K.Disruption of TAK1 in hepatocytes causes hepatic injury,inflammation,fibrosis,and carcinogenesis[J]. Proc Natl Acad Sci USA,2010,107(2):844-849.
[15]	Xu SW,Parapuram SK,Pala D,et al.Requirement of transforming growth factor beta-activated kinase 1 for transforming growth factor beta-induced alpha-smooth muscle actin expression and extracellular matrix contraction in fibroblasts[J]. Arthritis Rheum,2009,60(1):234-241.
[16]	Guo F,Hutchenreuther J,Carter DE,et al.TAK1 is required for dermal wound healing and homeostasis[J]. J Invest Dermatol,2013,133(6):1646-1654.
[17]	Sayama K,Hanakawa Y,Nagai H,et al.Transforming growth factor-beta-activated kinase 1 is essential for differentiation and the prevention of apoptosis in epidermis[J]. J Biol Chem,2006,281(31):22013-22020.

Acta Academiae Medicinae Sinica

Home

About Journal

Current Issue

Archive

Search

Contact Us

中文

Morphology of Hypertrophic Scar Tissues and Expressions of Vascular Endothelial Growth Factor and Transforming Growth Factor Beta Activated Kinase 1 in These Tissues

RichHTML

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 5

References 17

Related Articles 14

Metrics

Recommended 10

[1]	LI Ningning,ZHOU Jianfeng,ZHAO Lin,YING Hongyan,JIA Ning. Efficacy and Safety of Apatinib in Treating Advanced Colorectal Cancer [J]. Acta Academiae Medicinae Sinica, 2019, 41(2): 170-174.
[2]	XU Xiaoxuan,WU Yajun,WU Hongyun,HU Yuxiang,CHENG Yi,YAN Li,RAO Jie,WU Na,WU Xiaorong. Advances in Retinopathy of Prematurity [J]. Acta Academiae Medicinae Sinica, 2019, 41(2): 261-266.
[3]	XU Aqiao,ZHAO Zhenhua,YANG Jianfeng,WEI Mingzhu,ZHENG Jing,LU Junmin,HU Hongjie,ZHANG Shengjian. Evaluation of Uterine Tumor Angiogenesis with Quantitative Magnetic Resonance Imaging Perfusion Parameters [J]. Acta Academiae Medicinae Sinica, 2018, 40(5): 705-709.
[4]	Qi-chao YUAN, Li JIANG, Li-hua ZHU, Da-fan YU. Impacts of Erythropoietin on Vascular Endothelial Growth Factor Receptor 2 by the Extracellular Signal-regulated Kinase Signaling Pathway in a Neonatal Rat Model of Periventricular White Matter Damage [J]. Acta Academiae Medicinae Sinica, 2016, 38(2): 217-221.
[5]	WU Qi,WANG Jia-han,LI Zhi-qing,REN Jia-liang,WU Yong-heng. Expression of Vascular Endothelial Growth Factor in Deep Second-degree Scald Wounds in Rats [J]. Acta Academiae Medicinae Sinica, 2014, 36(6): 650-653.
[6]	HUO Shuang-zhi, SHI Ping, PANG Xi-ning. Effect of the Human Amniotic Membrane Loaded with Human Amniotic Mesenchymal Stem Cells on the Skin Wounds of SD Rats [J]. Acta Academiae Medicinae Sinica, 2011, 33(6): 611-614.
[7]	WANG Hongxia, LI Xiumei, HAN Xiuhua, JIANG Yajun, ZHU Guihua, ZHUANG Wanchuan. Clinical Significance of Tissue Factor and Vascular Endothelial Growth Factor Expressions on CD14+ Monocytes in Patients with Non Hodgkin Lymphoma [J]. Acta Academiae Medicinae Sinica, 2011, 33(4): 427-431.
[8]	WANG Zhi-kuan，MENG Hai-yan, HAN Chun，YANG Jun-lan. Expressions of Human Epidermal Growth Factor Receptor 2 and Vascular Endothelial Growth Factor in Primary or Recurrent Metastatic Breast Cancers [J]. Acta Academiae Medicinae Sinica, 2010, 32(4): 403-406.
[9]	HE Chun-mei；ZHENG Fa-lei；LIAN Yao-guo；LIU Yan-ping. Relationship between the Effect of Vascular Endothelial Growth Factor on Epithelial-mesenchymal Transition of HK-2 Cells and the Expressions of Bone Morphogenetic Protein-7 and Inhibitor of DNA Binding/Differentiation [J]. Acta Academiae Medicinae Sinica, 2008, 30(6): 703-710.
[10]	TIAN Ting, FAN Wei-xin, DAI Ye-qin, LIU Li-ping. Effect of Tacrolimus on the Growth Cycle of Murine Hair Follicles [J]. Acta Academiae Medicinae Sinica, 2007, 29(2): 209-212.
[11]	YANG Xiao-hong, MAN Xiao-yong, ZHENG Min. Advancements in Expression of Vascular Endothelial Growth Factor Receptors in Skin Diseases [J]. Acta Academiae Medicinae Sinica, 2007, 29(2): 279-282.
[12]	WANG Han, LIU Yong-jun, HAN Zhi-bo, LIANG Lin-hui, LV Lu-lu, HAN Zhong-chao. Effect of Silencing Hypoxia-inducible Factor-1α by RNA Interference on Human Breast Carcinoma Cell Line [J]. Acta Academiae Medicinae Sinica, 2006, 28(5): 670-674.
[13]	GU Feng, ZHANG Wen-jian, WU Lian-qiu, YE Li-ya, LI Han-zhong, LI Jing,XU Shi-qing, XU Ya-ping, LOU Jin-ning. Characteristics of Human Adrenal Microvascular Endothelial Cells in Morphology, Phenotypes, and Function [J]. Acta Academiae Medicinae Sinica, 2006, 28(4): 502-506.
[14]	ＬｉａｎｇＦｅｎｇ, ＷａｎｇＹｕｎ-ｆａｎｇ, ＮａｎＸｕe, ＹｕｅＨｕｉ-ｍｉｎ, ＸｕＹｉｎｇ-ｘｉｎ,ＳｈｉＳｈｕａｎｇ-ｓｈｕａｎｇ, ＬｉＲｏｎｇ,ＰｅｉＸｕｅ-ｔａｏ. Ｉｎ vｉｔｒｏＤｉｆｆｅｒｅｎｔｉａｔｉｏｎｏｆＨｕｍａｎＢｏｎｅＭａｒｒｏｗ-dｅｒｉｖｅｄＭｅｓｅｎｃｈｙｍａｌＳｔｅｍＣｅｌｌｓｉｎｔｏＢｌｏｏｄＶｅｓｓｅｌＥｎｄｏｔｈｅｌｉａｌＣｅｌｌｓ [J]. Acta Academiae Medicinae Sinica, 2005, 27(6): 665-669.